/Companies

Keros Therapeutics

NASDAQ: KROSUnicorn · $1.1B

Lexington, US · Founded 2016 · 125 employees on LinkedIn · 4 known investors

Find your way into Keros Therapeutics

Sign up to see every warm intro you have to Keros Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Keros Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart. Its pipeline targets neuromuscular diseases and ineffective hematopoiesis in myelodysplastic syndromes and myelofibrosis.

Founders & leadership

Keros Therapeutics was founded in 2016 by Jasbir Seehra.

JSJasbir Seehra
Jasbir SeehraCo-Founder, Chief Executive Officer and Director

Board

JK
Julius KnowlesBoard director
ALAlon Lazarus
Alon LazarusBoard directorManaging Partner at Arkin Capital
OH
Ohad HammerBoard director
RNRan Nussbaum
Ran NussbaumBoard directorManaging Partner at Pontifax Venture Capital

Investors · 4

Reported raises · per SEC filings

Form D private placements

$78.5M disclosed across 3 of 5 rounds · 1900–2020

▶$56MraisedMar 2020 · 20 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith RegnanteExecutive Officer
  • Jenn LacheyExecutive Officer
  • Claudia OrdonezExecutive Officer
  • Jasbir SeehraExecutive Officer, Director
  • Nima FarzanDirector
  • Alon LazarusDirector
  • Ran NussbaumDirector
  • Zafrira AvnurDirector
  • Carl GordonDirector
  • Julius KnowlesDirector
Offering amount
$56M
Amount sold
$56M
First sale
Mar 2020
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.5MraisedNov 2018 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alon LazarusDirector
  • Ran NussbaumDirector
  • Julius KnowlesDirector
  • Zafrira AvnurDirector
  • Jasbir S. SeehraExecutive Officer, Director
  • Ohad HammerDirector
Offering amount
$23M
Amount sold
$11.5M
First sale
Nov 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11MraisedNov 2017 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jasbir S. SeehraExecutive Officer, Director
  • Julius KnowlesDirector
  • Alon LazarusDirector
  • Ohad HammerDirector
  • Ran NussbaumDirector
Offering amount
$11M
Amount sold
$11M
First sale
Apr 2016
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$1.1Bvaluation at IPONov 2020 · $50.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

In the news

Frequently asked questions

What does Keros Therapeutics do?
Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart. Its pipeline targets neuromuscular diseases and ineffective hematopoiesis in myelodysplastic syndromes and myelofibrosis.
Who founded Keros Therapeutics?
Keros Therapeutics was founded by Jasbir Seehra in 2016.
Who are Keros Therapeutics's investors?
Keros Therapeutics's investors include Arkin Capital, Foresite Capital, OrbiMed, Pontifax Venture Capital.
How much funding has Keros Therapeutics raised?
Keros Therapeutics has disclosed $78.5M raised across 3 of its 5 known rounds.
Where is Keros Therapeutics headquartered?
Keros Therapeutics is headquartered in Lexington, US.